Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angeles Alvarez Secord

Showing results (201-210 of 239) with videos related to

Pageof 24
Sort By:
Gynecologic Oncology|July 12, 2025
Molecular characteristics by race and ethnicity of patients with high tumor mutational burden, high microsatellite instability, and mismatch repair deficiency: Real-world data from the multi-institutional Endometrial cancer Molecularly Targeted Therapy Consortium (ECMT2)Sarah S Lee, Angeles Alvarez Secord, Steven Friedman, et al.
Gynecologic Oncology|January 11, 2021
The presence of an endometrioid component does not alter the clinicopathologic profile or survival of patients with uterine serous cancer: A gynecologic oncology group (GOG/NRG) study of 934 womenIan S Hagemann, Wei Deng, Richard J Zaino, et al.
Gynecologic Oncology|July 14, 2022
What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long term (≥10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancerOmali Pitiyarachchi, Michael Friedlander, James J Java, et al.
Gynecologic Oncology|January 17, 2017
Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer - An NRG oncology/Gynecologic Oncology Group studyVivian E von Gruenigen, Helen Q Huang, Jan H Beumer, et al.
Gynecologic Oncology|September 12, 2024
Results of a randomized phase II trial of paclitaxel and carboplatin versus bleomycin, etoposide and cisplatin for newly diagnosed and recurrent Chemonaive stromal ovarian tumors: An NRG oncology/gynecologic oncology group study14Jubilee Brown, Austin Miller, Laura L Holman, et al.
Gynecologic Oncology|January 3, 2009
Stage II uterine papillary serous carcinoma: Carboplatin/paclitaxel chemotherapy improves recurrence and survival outcomesAmanda Nickles Fader, Christa Nagel, Allison E Axtell, et al.
Gynecologic Oncology|June 12, 2026
Atezolizumab in combination with neoadjuvant chemotherapy and interval cytoreductive surgery for patients with newly diagnosed advanced-stage epithelial ovarian cancer: the AdORN studyStéphanie Gaillard, Jack Parker, Gloria Broadwater, et al.
Gynecologic Oncology|January 24, 2025
Molecular classification of endometrial cancers (EC) and association with relapse-free survival (RFS) and overall survival (OS) outcomes: Ancillary analysis of GOG-0258Aine Clements, Danielle Enserro, Kyle C Strickland, et al.
Gynecologic Oncology|February 5, 2021
Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology studyKimberly K Leslie, Virginia L Filiaci, Adrianne R Mallen, et al.
The Lancet. Oncology|April 6, 2019
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trialKathleen N Moore, Angeles Alvarez Secord, Melissa A Geller, et al.
Pageof 24

Showing results (201-210 of 239) with videos related to

Sort By:
Pageof 24
Gynecologic Oncology|July 12, 2025
Molecular characteristics by race and ethnicity of patients with high tumor mutational burden, high microsatellite instability, and mismatch repair deficiency: Real-world data from the multi-institutional Endometrial cancer Molecularly Targeted Therapy Consortium (ECMT2)Sarah S Lee, Angeles Alvarez Secord, Steven Friedman, et al.
Gynecologic Oncology|January 11, 2021
The presence of an endometrioid component does not alter the clinicopathologic profile or survival of patients with uterine serous cancer: A gynecologic oncology group (GOG/NRG) study of 934 womenIan S Hagemann, Wei Deng, Richard J Zaino, et al.
Gynecologic Oncology|July 14, 2022
What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long term (≥10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancerOmali Pitiyarachchi, Michael Friedlander, James J Java, et al.
Gynecologic Oncology|January 17, 2017
Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer - An NRG oncology/Gynecologic Oncology Group studyVivian E von Gruenigen, Helen Q Huang, Jan H Beumer, et al.
Gynecologic Oncology|September 12, 2024
Results of a randomized phase II trial of paclitaxel and carboplatin versus bleomycin, etoposide and cisplatin for newly diagnosed and recurrent Chemonaive stromal ovarian tumors: An NRG oncology/gynecologic oncology group study14Jubilee Brown, Austin Miller, Laura L Holman, et al.
Gynecologic Oncology|January 3, 2009
Stage II uterine papillary serous carcinoma: Carboplatin/paclitaxel chemotherapy improves recurrence and survival outcomesAmanda Nickles Fader, Christa Nagel, Allison E Axtell, et al.
Gynecologic Oncology|June 12, 2026
Atezolizumab in combination with neoadjuvant chemotherapy and interval cytoreductive surgery for patients with newly diagnosed advanced-stage epithelial ovarian cancer: the AdORN studyStéphanie Gaillard, Jack Parker, Gloria Broadwater, et al.
Gynecologic Oncology|January 24, 2025
Molecular classification of endometrial cancers (EC) and association with relapse-free survival (RFS) and overall survival (OS) outcomes: Ancillary analysis of GOG-0258Aine Clements, Danielle Enserro, Kyle C Strickland, et al.
Gynecologic Oncology|February 5, 2021
Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology studyKimberly K Leslie, Virginia L Filiaci, Adrianne R Mallen, et al.
The Lancet. Oncology|April 6, 2019
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trialKathleen N Moore, Angeles Alvarez Secord, Melissa A Geller, et al.
Pageof 24